Surmodics (SRDX) has signed a definitive agreement to be acquired by GTCR, a private equity firm with investment expertise in healthcare and healthcare technology. Affiliates of GTCR will purchase all outstanding shares of Surmodics. Shareholders of Surmodics will receive $43.00 per share in cash, valuing the company's equity at approximately $627 million.
The Board of Directors at Surmodics has unanimously approved this transaction and will be recommending that stockholders vote in favor of it. Once the acquisition is completed, Surmodics will become a privately held company, and its common stock will no longer be listed on The Nasdaq Stock Exchange.
For more health-related news, visit rttnews.com.
